Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

U.S. News

Ranbaxy Pharmaceuticals Receives FDA Approval for Generic Version of GlaxoSmithKline's Valtrex

February 2, 2007

The Food and Drug Administration has approved a generic form of Valtrex (valacyclovir hydrochloride), GlaxoSmithKline's treatment for genital herpes and shingles, Indian generics maker Ranbaxy Laboratories Ltd. announced Thursday. The approved doses are for 500-mg and 1-gram caplets, the firm said. On Wednesday, Mylan Laboratories received tentative approval of its own 500-mg and 1,000-mg generic versions of Valtrex; however, the company cannot yet market its products due to outstanding patent issues. Patent issues for Mylan will resolve when patents begin to expire June 2009.

Back to other news for February 2, 2007

Adapted from:
Associated Press
02.01.2007


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More HIV News

Tools
 

Advertisement